SCHEMBL5049082

SCHEMBL5049082

CCCCCCSc1nc(C(OCC)OCC)cc(C(F)(F)F)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
MAPK1 P28482 2/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 5/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 1/20 0.35
GPR84 Q9NQS5 1/20 0.34
PTGES O14684 2/20 0.34
TSHR P16473 3/20 0.34
HTT P42858 3/20 0.34
TP53 P04637 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046187 0.82 GPR84 (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL5045840 0.78 SMN1; SMN2 (0.35) SMN1; SMN2ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL5049122 0.74 GPR84 (0.44) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL5049907 0.73 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1L3MBTL1MAPK1POLB
SCHEMBL5692459 0.73 TLR8 (0.41) SMN1; SMN2ALDH1A1MAPK1MAPTLMNA
SCHEMBL28802778 0.71 LMNA (0.43) SMN1; SMN2ALDH1A1L3MBTL1MAPK1POLB
SCHEMBL29672139 0.71 LMNA (0.43) SMN1; SMN2ALDH1A1L3MBTL1MAPK1POLB
SCHEMBL6021992 0.71 GPR84 (0.32) GPR84
SCHEMBL5043353 0.67 ALDH1A1 (0.44) ALDH1A1L3MBTL1MAPK1MAPTLMNA
SCHEMBL5042168 0.63 GPR84 (0.48) SMN1; SMN2ALDH1A1L3MBTL1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US disclosed
EP-1725239-B1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY HOFFMANN LA ROCHE (CH) 2007-07-18 EP disclosed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors CHRNA2, CNR2, GABRB2 SMN1; SMN2 98/4885ALDH1A1 3230/4885L3MBTL1 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.